The chemical designation of udenafil is 5-[2-propyloxy-5-(1-methyl-2-pyrollidiny lethylamidosulphonyl) phenhyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one (Zydena®; Dong-A Pharmaceutical Company, Seoul, Korea) [Kim et al. 2008]. Udenafil is a newly developed PDE5 inhibitor that is both potent and selective and has a similar molecular structure to sildenafil citrate (Viagra®) . An in vitro study of udenafil has shown it to be comparable to sildenafil (Viagra®) in selectivity to PDE5 [Doh et al. 2002]. Udenafil has also been shown in preclinical studies to have potent erectogenic properties in rats and rabbits with a broad safety margin [Salem et al. 2006]. In addition, unlike tadalafil, udenafil does not inhibit PDE11 [Doh et al. 2002; Salem et al. 2006].
|Synonyms:||Zydena;Udenafi;Da-8159;Da 8159;Udenafil;Udenafil(DA 8159,Zydena);5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-D)pyrimidine-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide|